ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Biological: adalimumab
Biological: placebo

First Posted Date: 2006-10-11

Last Posted Date: 2011-04-11

Lead Sponsor: Abbott

Target Recruit Count: 576

Registration Number: NCT00385736

Locations: 🇦🇹
Site Ref # / Investigator 4937, Vienna, Austria
🇦🇹
Site Ref # / Investigator 7508, Linz, Austria
🇨🇿
Site Ref # / Investigator 3858, Brno, Czech Republic

and more 77 locations

A Study of Volociximab in Metastatic Melanoma

Phase 2

Terminated

Conditions: Stage IV Melanoma

Interventions: Drug: volociximab

First Posted Date: 2006-08-29

Last Posted Date: 2012-04-27

Lead Sponsor: Abbott

Target Recruit Count: 19

Registration Number: NCT00369395

Locations: 🇺🇸
Site Reference ID/Investigator# 70376, Boston, Massachusetts, United States
🇺🇸
Site Reference ID/Investigator# 70356, La Jolla, California, United States
🇺🇸
Site Reference ID/Investigator# 70375, Aurora, Colorado, United States

and more 4 locations

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

Phase 3

Completed

Conditions: Human Immunodeficiency Virus Infections

Interventions: Drug: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)

First Posted Date: 2006-08-01

Last Posted Date: 2011-04-11

Lead Sponsor: Abbott

Target Recruit Count: 599

Registration Number: NCT00358917

Locations: 🇺🇸
Medical Information - Abbott (1-800-633-9110), Abbott Park, Illinois, United States

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: ABT-751
Drug: Docetaxel

First Posted Date: 2006-07-20

Last Posted Date: 2011-01-07

Lead Sponsor: Abbott

Target Recruit Count: 75

Registration Number: NCT00354562

Locations: 🇺🇸
Site Ref # / Investigator 3571, Nashville, Tennessee, United States
🇮🇪
Site Ref # / Investigator 5097, Cork, Ireland
🇨🇦
Site Ref # / Investigator 3563, Sydney, Nova Scotia, Canada

and more 29 locations

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: adalimumab
Biological: placebo

First Posted Date: 2006-07-04

Last Posted Date: 2011-04-11

Lead Sponsor: Abbott

Target Recruit Count: 135

Registration Number: NCT00348283

Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.

Phase 3

Completed

Conditions: Acute Heart Failure

First Posted Date: 2006-07-04

Last Posted Date: 2007-11-20

Lead Sponsor: Abbott

Target Recruit Count: 1300

Registration Number: NCT00348504

Locations: 🇺🇸
Global Medical Information - Abbott, Abbott Park, Illinois, United States

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

Phase 3

Completed

Conditions: Crohn's Disease

First Posted Date: 2006-06-20

Last Posted Date: 2007-11-29

Lead Sponsor: Abbott

Target Recruit Count: 1000

Registration Number: NCT00338650

Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

First Posted Date: 2006-06-20

Last Posted Date: 2007-09-11

Lead Sponsor: Abbott

Target Recruit Count: 160

Registration Number: NCT00338754

A Study of Pain Relief in Low Back Pain

Phase 3

Completed

Conditions: Chronic Low Back Pain

Interventions: Drug: Extended release hydrocodone and acetaminophen (Vicodin CR)
Drug: hydrocodone/acetaminophen extended release (Vicodin CR)
Drug: placebo

First Posted Date: 2006-05-15

Last Posted Date: 2011-07-25

Lead Sponsor: Abbott

Target Recruit Count: 770

Registration Number: NCT00325949

Locations: 🇺🇸
Site Ref # / Investigator 1982, Missoula, Montana, United States
🇺🇸
Site Ref # / Investigator 2204, Miami, Florida, United States
🇺🇸
Site Ref # / Investigator 2205, Miami, Florida, United States

and more 60 locations

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Visilizumab

First Posted Date: 2006-03-28

Last Posted Date: 2012-04-27

Lead Sponsor: Abbott

Target Recruit Count: 38

Registration Number: NCT00307827

Locations: 🇺🇸
Site Reference ID/Investigator# 71896, Cleveland, Ohio, United States
🇭🇷
Site Reference ID/Investigator# 72338, Osijek, Croatia
🇭🇷
Site Reference ID/Investigator# 72334, Zagreb, Croatia

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy